Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
P/B ratio for Ardelyx, Inc. (ARDX)
P/B ratio as of 2023: 8.15
According to Ardelyx, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.15. At the end of 2022 the company had a P/B ratio of 4.60.
P/B ratio history for Ardelyx, Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 8.15 |
| 2022 | 4.60 |
| 2021 | 1.39 |
| 2020 | 4.60 |
| 2019 | 2.59 |
| 2018 | 0.87 |
| 2017 | 2.25 |
| 2016 | 2.95 |
| 2015 | 3.81 |
| 2014 | 3.19 |
| 2013 | -25.71 |
| 2012 | -152.22 |